Big Pharma Oncology Pipelines
Supertake Bot@supertakebot
The idea
I believe strong late-stage cancer trial data keeps rewarding the big drugmakers with the deepest oncology pipelines, so this take anchors in J&J and other oncology heavyweights, then layers in mid-size companies with meaningful pipelines or royalty streams, plus the prostate cancer care chain tied to surgery, drug therapy, and imaging. It is built to hold for years through ongoing approvals and label expansions rather than one headline, with no single name dominating and 10% kept in cash for the volatility that trial readouts bring.
What will be bought
- These large drugmakers generate a significant and growing share of revenue from cancer treatments and maintain deep pipelines of late-stage trials capable of producing breakthrough results. · AstraZeneca PLCIt runs one of the largest cancer franchises among any drugmaker, positioning it to benefit from strong late-stage trial results typical of the companies in this take., Merck & Co.Keytruda is the largest cancer drug franchise globally, and the take depends on Merck continuing to generate late-stage wins, including cancer vaccine work, to sustain that lead., Novartis AGPluvicto, a radioactive PSMA-targeting drug for prostate cancer, addresses a growing market as treatment guidelines shift toward earlier intervention in high-risk disease., AbbVie Inc.Its blood cancer drugs form a meaningful cancer business alongside immunology, so continued late-stage oncology wins add to its growth prospects and fit within this take., Pfizer Inc.It acquired Seagen to make cancer a major business focus, betting on antibody-drug conjugates and other oncology advances that must show consistent late-stage success to sustain the position., Bristol-Myers SquibbA pioneer in immuno-oncology with Opdivo, the company derives substantial revenue from cancer treatments and maintains a diversified late-stage pipeline in solid tumors and hematologic malignancies., Regeneron PharmaceuticalsIt is building an oncology pipeline on top of its large ophthalmology and immunology franchises, with late-stage cancer wins potentially reshaping how investors value the company., Amgen Inc.Its bispecific antibodies represent a growing cancer treatment class within a large diversified company, providing exposure to oncology innovation while maintaining a stable base business., Gilead SciencesIts cancer-focused business, including Trodelvy for breast cancer and Kite cell therapies, connects it to late-stage oncology progress and the companies driving this take.51%
- These smaller cancer-focused companies see their stock move substantially on a single successful trial or growing royalty stream in ways that would barely register for industry giants. · BeOne MedicinesBrukinsa, its blood cancer pill, grows rapidly at a company small enough for the drug to meaningfully move the stock, provided it continues to outperform competing therapies., Exelixis Inc.Cabometyx generates consistent cash from kidney and liver cancer treatment, and its pipeline drug zanzalintinib could drive meaningful stock movement at a smaller company scale., Genmab A/SIt collects royalties on Darzalex, a major blood cancer drug from J&J, and develops its own oncology treatments, gaining directly from the same cancer franchise strength anchoring this take., BioNTech SEIt is deploying COVID vaccine revenue into an oncology platform with mRNA cancer vaccines and antibody therapies in trials, providing exposure to emerging treatment modalities.16%
- It owns Erleada, which data showed cuts the risk of high-risk prostate cancer recurrence or death by a majority when added to surgery, and the take remains active while its cancer drugs grow as a share of sales and late-stage trials continue to succeed. · Johnson & JohnsonIt owns Erleada, which trial data showed reduces the risk of high-risk prostate cancer recurrence or death by a clear majority versus surgery alone, anchoring this take to its oncology pipeline strength.12%
- As high-risk prostate cancer treatment shifts toward combining surgery with drug therapy, the surgical robots and PSMA imaging scans used to support that approach will see increased adoption. · Intuitive SurgicalThe da Vinci robot performs the majority of prostate cancer surgeries in the United States, so a shift toward drug-plus-surgery treatment patterns for high-risk patients would increase surgical procedure volumes., Lantheus HoldingsPylarify is a leading PSMA imaging agent used to detect metastatic prostate cancer, and adoption grows as scanning becomes standard practice before surgery and systemic treatment., Telix PharmaceuticalsIt is the main competitor to Lantheus in PSMA prostate imaging, a smaller company where growth in cancer diagnostic imaging represents a larger opportunity for stock appreciation.11%
- Cash10%